Slideshow of doctors

GORE® VIABAHN® Device family

Join the next generation of care in the treatment of aortoiliac occlusive disease

Aortoiliac occlusive disease (AIOD) – An increasingly complex condition

The incidence of AIOD is increasing,1 leaving more patients vulnerable to a disease that, untreated, can cause pain, tissue loss and amputation

Guidelines for treating AIOD

TASC II A and B lesions:

Guidelines recommend an endovascular approach.2

TASC II C and D lesions:

Guidelines recommend surgery, although multiple consensus and practice guidelines now generally endorse an endovascular-first strategy in experienced endovascular centers.2-5

Lesions

Potential obstacles of endovascular treatment

Challenges

Tortuous anatomies

Tortuous anatomies

Risks

Perforation

Perforation or rupture of the iliac arteries and aortic bifurcation:

  • occurs in nearly 4% of cases
  • can be life-threatening6-9
Severe stenosis

Severe stenosis

Rupture

Rupture:

  • may occur post operatively
  • can cause acute bleeding & hypotension10,11
Highly calcified occlusions

Highly calcified occlusions

*As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS Heparin Surface.

  1. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circulation Research 2015;116(9):1509-1526.
  2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group.  Inter-Society consensus for the management of peripheral arterial disease (TASC II).  Journal of Vascular Surgery 2007;45(1)Supplement S:S5-S67.
  3. Klein AJ, Feldman DN, Aronow HD, et al; Peripheral Vascular Disease Committee for the Society for Cardiovascular Angiography and Interventions.  SCAI expert consensus statement for aorto-iliac arterial intervention appropriate use.  Catheterization & Cardiovascular Interventions 2014;84(4):520-528.  
  4. Rossi M, Iezzi R. Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease. Cardiovascular & Interventional Radiology 2014;37(1):13-25. 
  5. European Stroke Organisation, Tendera M, et al; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).  European Heart Journal 2011;32(22):2851-2906.
  6. Jongkind V, Akkersdijk GJ, Yeung KK, Wisselink W.  A systematic review of endovascular treatment of extensive aortoiliac occlusive disease.  Journal of Vascular Surgery 2010;52(5):1376-1383.
  7. Indes JE, Pfaff MJ, Farrokhyar F, et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. Journal of Endovascular Therapy 2013;20(4):443-455.
  8. Piazza M, Squizzato F, Dall'Antonia A, et al.  Outcomes of self expanding PTFE covered stent versus bare metal stent for chronic iliac artery occlusion in matched cohorts using propensity score modelling.  European Journal of Vascular & Endovascular Surgery 2017;54(2):177-185.
  9. Squizzato F, Piazza M, Pulli R, et al; ILIACS Registry Group. Covered versus bare metal kissing stents for reconstruction of the aortic bifurcation in the ILIACS registry.  Journal of Vascular Surgery.  In press.
  10.  Sobrinho G, Albino JP. Delayed rupture of the external iliac artery after balloon angioplasty and stent placement. Journal of Vascular & Interventional Radiology 2008;19(3):460-462.
  11.  Allaire E, Melliere D, Poussier B, Kobeiter H, Desgranges P, Becquemin JP. Iliac artery rupture during balloon dilatation: what treatment? Annals of Vascular Surgery 2003;17(3):306-314.

eIFU Symbol

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.